Protein Inhibitors - Crizotinib (CAS: 877399-52-5)

Location：Home > Biochemicals > Protein Inhibitors

Crizotinib (CAS: 877399-52-5)

Hot product

Catalog #：EBC51046

Crizotinib (CAS: 877399-52-5)

SKU-Pack Size	Availability	Size	Price
EBC51046-1ML	In Stock	1mL(10mM in DMSO)	￡95.70
EBC51046-5MG	In Stock	5mg	￡95.70
EBC51046-10MG	In Stock	10mg	￡139.70
EBC51046-50MG	In Stock	50mg	￡436.70
EBC51046-100MG	In Stock	100mg	￡656.70

If you want to get a larger packsize, Please contact your local distributor or
email us atinfo@ebiocell.com

Please Select The Country You Are In To Find Your Local Distributor.

	CUlabSciences	Phone：+44 (0) 1232 330008
	Cambridge House St Thomas' Place Ely,	E-mail：sales@culabsciences.co.uk
United Kingdom	Cambridge CB27 9RD UK	Web：www.culabsciences.co.uk

Product Information

Synonym(s)

PF 02341066, PF 2341066

Chemical Name

3-[(1R)-1-(2,6-Dichloro-3-fluorophenyl)ethoxy]-5-[1-(4-piperidinyl)-1H-pyrazol-4-yl]-2-pyridinaminephenyl)ethoxy]-5-[1-(4-piperidinyl)-1H-pyrazol-4-yl]-2-pyridinamine

Application

Crizotinib is a Potent c-MET/ALK inhibitor

CAS Number

877399-52-5

Purity

≥99.0%

Molecular Weight

450.34

Molecular Formula

C21H22Cl2FN5O

SMILES

ClC1=C(F)C=CC(Cl)=C1[C@H](OC2=CC(C3=CN(N=C3)C4CCNCC4)=CN=C2N)C

Target & IC50

ALK: IC50=24 nM
c-Met: IC50=11 nM

Solubility

DMSO: 4.5 mg/mL (10 mM)
2eq.HCl: 45 mg/mL (100 mM)

Preparing Stock Solutions

ConcentrationSolventMass	1 mg	5 mg	10 mg
1 mM	2.2205 ml	11.1027 ml	22.2054 ml
5 mM	0.4441 ml	2.2205 ml	4.4411 ml
10 mM	0.2221 ml	1.1103 ml	2.2205 ml
50 mM	0.0444 ml	0.2221 ml	0.4441 ml

Shipping

Gel Pack

Storage

Store at -20°C

Research Use

For Research Use Only. Not Intended for Diagnostic Or Therapeutic Use.

Product Description

Crizotinib is an orally bioavailable agent belonging to the class of c-met/hepatocyte growth factor receptor (HGFR) tyrosine kinase inhibitors with potential antineoplastic activity. Crizotinib was approved For treatment of some non-small cell lung carcinoma (NSCLC) in the US, and undergoing clinical trials testing its safety and efficacy in anaplastic large cell lymphoma, neuroblastoma, and other advanced solid tumors in both adults and childre. Crizotinib inhibits the membrane receptor MET and activation of the MET signaling pathway, which may block tumor cell growth, migration and invasion, and tumor angiogenesis in susceptible tumor cell populations. Check For active clinical trials or closed clinical trials using this agent. (NCI Thesaurus) . For the detailed information about the solubility of Crizotinib (PF-2341066) in water, the solubility of Crizotinib (PF-2341066) in DMSO, the solubility of Crizotinib (PF-2341066) in PBS buffer, the animal experiment（test） of Crizotinib (PF-2341066),the in vivo,in vitro and clinical trial test of Crizotinib (PF-2341066),the cell experiment（test） of Crizotinib (PF-2341066),the IC50, EC50 and Affinity of Crizotinib (PF-2341066).

Specific Protocols

>>	Western Blotting Protocol	>>	Immunoprecipitation Protocol
>>	Immunohistochemistry Protocol	>>	Immunofluorescence Protocol
>>	Immunocytochemistry Protocol	>>	Flow Cytometry Protocol
>>	ChIP Protocol	>>	ELISA Protocol
>>	HPLC Protocol	>>	PCR Protocol